Pause

Publications

Selected Publications

  • Jahangiri A, Nguyen A, Chandra A, Sidorov MK, Yagnik G, Rick J, Han SW, Chen W, Flanigan PM, Schneidman-Duhovny D, Mascharak S, De Lay M, Imber B, Park CC et al,. Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer. Proc Natl Acad Sci U S A. 2017 Sep 26. pii: 201701821
  • Raleigh D, Ahmed KM, Zhang H, Ziaee S and Park CC. PARP-1 modulates β1-integrin/NF-κB-mediated radioresistance in human breast cancer. J Cancer Ther Res. 2016; 5:1.
  • Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.Breast Cancer Res Treat. 2016 Feb;155(3):431-40
  • Kaufman SA, Harris EE, Bailey L, Chadha M, Dutton SC, Freedman GM, Goyal S, Halyard MY, Horst KC, Novick KL, Park CC, Suh WW, Toppmeyer D, Zook J, Haffty BG. ACR Appropriateness Criteria® Ductal Carcinoma in Situ. Oncology (Williston Park). 2015 Jun;29(6):446-58, 460-1
  • Nam JM, Ahmed KM, Costes S, Zhang H, Onodera Y, Olshen AB, Hatanaka KC, Kinoshita R, Ishikawa M, Sabe H, Shirato H, Park CC. Beta1-integrin via NF-kappaB signaling is essential for acquisition of invasiveness in a model of radiation treated in situ breast cancer. Breast Cancer Res. 2013 Jul 25;15(4):R60. PMID: 23883667
  • Ahmed KM, Zhang H, Park CC. NF-κB regulates radioresistance mediated by β1-integrin in three-dimensional culture of breast cancer cells. Cancer Res. 2013 Jun 15;73(12):3737-48. doi: 10.1158/0008-5472.CAN-12-3537. PMID:23576567
  • Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res. 2013 May 15;73(10):3145-54. doi: 10.1158/0008-5472.CAN-13-0011. Epub 2013 May 3.
  • Nabavizadeh N, Klifa,C, Newitt D, Lu Y, Chen YY, Hsu H, Fisher C, Tokayasu T, Olshen A, Spellman PT, Gray, JW, Hylton N and Park, CC* Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. Integr. Biol., 2011, 3, 490-496, DOI: 10.1039/c0ib00089b.
  • Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi M, WangYC, Shou J, Osborne K, Schiff R. β1 Integrin Mediates an Alternative Survival Pathway in Breast Cancer Cells Resistant to Lapatinib. Breast Cancer Res. 2011 Aug 31;13(4):R84
  • Nam JM, Onodera Y, Bissell MJ, Park CC. Breast Cancer Cells in Three-dimensional Culture Display an Enhanced Radioresponse after Coordinate Targeting of Integrin α5β1 and Fibronectin. Can Res, 2010: 70(13); 5238-48
  • Nam JM, Chung Y, Hsu HC, Park CC. β1 integrin targeting to enhance radiation therapy. Int J Radiat Biol. 2009 Nov; 85(11):923-8.
  • Weigelt B, Lo A, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2 targeting agents is dependent strongly on the 3D microenvironment. Breast Ca Res Treatment, 2009 Aug 22.
  • Hattangadi J, Park C, Rembert J, Klifa C, Hwang J, Gibbs J, Hylton N. Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy. AJR Am J Roentgenol. 2008 Jun; 190(6):1630-6. PMID: 18492917
  • Park CC, Zhang HJ, Yao ES, Kim S, Park CJ, Bissell MJ. Inhibition of b1 integrin enhances breast cancer radiotherapy. Cancer Res. 2008 Jun 1; 68(11): 4398-405.
  • Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D, Park C. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007 Jan 15; 67(2): 659-64. PMID: 17234776
  • Park CC, Zhang HZ, Baehner F, Gray, JW, Pallavicini M, Bissell MJ. Disrupting b1 integrin signaling inhibits growth, induces apoptosis, and distinguishes malignant from normal phenotype in 3D cultures and in vivo. Cancer Res 2006; 66: (3). February 1, 2006. Ranked Top Ten by Faculty of 1000 Biologists